SPRY Earnings & Financial Statements
ARS Pharmaceuticals, Inc.
$4.54
+$0.18(+4.13%)
34
Overall
50
Value
18
Tech
34
Quality
Market Cap
$433.59M
Volume
513.51K
52W Range
$3.99 - $13.15
Target Price
$24.33
SPRY earnings and financial statements: ARS Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SPRY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $84.28M | $89.15M | $30.0K | $1.32M | $5.51M |
| Cost of revenue | $20.42M | $977.0K | - | - | - |
| Operating income | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M |
| EBITDA | -$170.01M | $8.37M | -$67.52M | -$35.20M | -$20.24M |
| Net income | -$171.30M | $8.00M | -$54.37M | -$34.68M | -$20.24M |
| EPS (diluted) | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-2.56 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $327.65M | $351.15M | $233.19M | $281.44M | $61.45M |
| Total liabilities | $213.39M | $94.36M | $2.43M | $8.55M | $16.68M |
| Shareholders’ equity | $114.26M | $256.80M | $230.76M | $272.89M | -$31.27M |
| Cash and equivalents | $41.32M | $50.82M | $70.97M | $210.52M | $60.06M |
| Long-term debt | $96.37M | - | $37.0K | $251.0K | $5.41M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$170.87M | $13.55M | -$59.27M | -$40.08M | -$17.56M |
| Capital expenditure | -$339.0K | -$563.0K | -$175.0K | -$199.0K | -$55.0K |
| Free cash flow | -$171.21M | $12.98M | -$59.44M | -$40.28M | -$17.62M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SPRY | $4.54 | +4.1% | 513.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ARS Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW